 | Study programme 2026-2027 | Français | |
 | Faculty of Medicine, Pharmacy and Biomedical Sciences | ||
| Master's in Pharmacy (MONS) (day schedule) |
- Panel Chairperson : Francis VANDERBIST
- Panel Secretary : Gilles BERGER
| Show AAs | |||||||||||||||||
| Bloc 1 | Hours (*) | Term | Credits | Weight. | |||||||||||||
| HT(*) | HTPE(*) | HTPS(*) | HD(*) | HR(*) | Total | ||||||||||||
| Enseignements obligatoires communs | |||||||||||||||||
 UM-M1-PHARMA-001-M Biochimie médicale - Partie 1 | 27 | 0 | 0 | 0 | 0 | 27 | Q1 | 4 | 4 | ||||||||
| UM-M1-PHARMA-004-M Bioanalyse | 20 | 48 | 0 | 0 | 0 | 68 | Q2 | 5 | 5 | ||||||||
| UM-M1-PHARMA-005-M Pharmacologie spéciale | 50 | 0 | 0 | 0 | 0 | 50 | Q2 | 4 | 4 | ||||||||
| UM-M1-PHARMA-006-M Technologie pharmaceutique: galénique & biopharmacie - Partie 1 | 40 | 70 | 0 | 0 | 0 | 110 | Q1 | 8 | 8 | ||||||||
| UM-M1-PHARMA-007-M Technologie pharmaceutique: galénique & biopharmacie - Partie 2 | 40 | 0 | 0 | 0 | 0 | 40 | Q2 | 5 | 5 | ||||||||
| UM-M1-PHARMA-008-M Approche pharmaceutique de la nutrition et aspects de bromatologie | 24 | 2 | 4 | 0 | 0 | 30 | Q1 | 3 | 3 | ||||||||
| UM-M1-PHARMA-009-M Pharmacochimie: études des médicaments organiques - Partie 2 | 54 | 60 | 0 | 0 | 0 | 114 | Q1 | 8 | 8 | ||||||||
| UM-M1-PHARMA-021-M Etude des médicaments d'origine biologique | 20 | 0 | 0 | 0 | 0 | 20 | Q1 | 3 | 3 | ||||||||
| UM-M1-PHARMA-015-M Biochimie médicale - Partie 2 | 33 | 0 | 0 | 0 | 0 | 33 | Q2 | 4 | 4 | ||||||||
| UM-M1-PHARMA-002-M Toxicologie prédictive | 21 | 0 | 6 | 0 | 0 | 27 | Q2 | 3 | 3 | ||||||||
| UM-M1-PHARMA-017-M Approche transdisciplinaire du conseil pharmaceutique | 50 | 0 | 0 | 0 | 0 | 50 | Q1,Q2 | 4 | 4 | ||||||||
| Enseignements optionnels communs | 9 | ||||||||||||||||
Students must choose a 9-credit specialisation from the two options listed below. PLEASE NOTE: access to research placements is subject to approval by the Bachelor's and Master's degree examination board chairs and is based on the quality of the student's application and their aptitude for independent work and scientific research. A complete application must be submitted via the intranet page ?Research Specialisation Access Request? by the beginning of September at the latest. | |||||||||||||||||
| Orientation appliquée | |||||||||||||||||
| UM-M1-PHARMA-011-M Travaux pratiques en Approche transdisciplinaire du conseil pharmaceutique | 0 | 45 | 0 | 0 | 0 | 45 | Q1,Q2 | 5 | 5 | ||||||||
| UM-M1-PHARMA-003-M Pharmaceutical Research (CLIL course) | 0 | 20 | 0 | 0 | 0 | 20 | Q2 | 2 | 2 | ||||||||
| UM-M1-PHARMA-018-M Travaux pratiques en Biochimie médicale - Partie 2 | 0 | 50 | 0 | 0 | 0 | 50 | Q2 | 2 | 2 | ||||||||
| Orientation recherche | |||||||||||||||||
| UM-M1-PHARMA-012-M Stage projet de recherche | 0 | 0 | 160 | 0 | 0 | 160 | Q2 | 9 | 9 | ||||||||
| Enseignements transitoires 2026-2027 | 0 | ||||||||||||||||
| UM-M1-PHARMA-T18-M Travaux pratiques en Biochimie médicale - Partie 2 (UE transitoire 2026-2027) | 0 | 60 | 0 | 0 | 0 | 60 | Q1,Q2 | 2 | 2 | ||||||||
| UM-M1-PHARMA-T01-M Biochimie médicale - Partie 1 (UE transitoire 2026-2027) | 42 | 0 | 0 | 0 | 0 | 42 | Q1 | 4 | 4 | ||||||||
| 60 | |||||||||||||||||
| Bloc 2 | Hours (*) | Term | Credits | Weight. | |||||||||||||
| HT(*) | HTPE(*) | HTPS(*) | HD(*) | HR(*) | Total | ||||||||||||
| Enseignements obligatoires communs | |||||||||||||||||
| UM-M2-PHARMA-001-M Législation, déontologie et éthique pharmaceutique | 36 | 0 | 0 | 0 | 0 | 36 | Q1 | 5 | 5 | ||||||||
| UM-M2-PHARMA-002-M Pharmacie clinique, Conseil et suivi pharmaceutique, Bonnes pratiques officinales, Pharmaco-économie | 29 | 16 | 0 | 0 | 0 | 45 | Q1 | 5 | 5 | ||||||||
UM-M2-PHARMA-003-M Stage officinal et pratiques avancées  | 5 | 36 | 964 | 0 | 0 | 1005 | Y,Q1,Q2 | 25 | 25 | ||||||||
| Enseignements optionnels communs | 25 | ||||||||||||||||
| Soins pharmaceutiques | 0 | ||||||||||||||||
| UM-M2-PHARMA-005-M Mémoire Officine, hôpital, biologie clinique, recherche (1,5 mois) | 0 | 0 | 180 | 0 | 0 | 180 | Q2,Y | 15 | 15 | ||||||||
| Cours à option - Soins pharmaceutiques | 10 | ||||||||||||||||
| UM-M2-PHARMA-009-M Mycologie | 6 | 3 | 0 | 6 | 0 | 15 | Q1 | 2 | 2 | ||||||||
| UM-M2-PHARMA-010-M Dermatologie et conseils à l'officine (dermopharmacie) | 10 | 0 | 0 | 0 | 0 | 10 | Q1 | 2 | 2 | ||||||||
| UM-M2-PHARMA-011-M Soins d'urgence | 15 | 0 | 0 | 0 | 0 | 15 | Q1 | 2 | 2 | ||||||||
| UM-M2-PHARMA-012-M Management, leadership et innovations en officine | 10 | 0 | 0 | 0 | 0 | 10 | Q1 | 2 | 2 | ||||||||
| UM-M2-PHARMA-013-M Médicaments vétérinaires | 6 | 4 | 0 | 0 | 0 | 10 | Q1 | 2 | 2 | ||||||||
| UM-M2-PHARMA-014-M Médecines alternatives et complémentaires | 10 | 0 | 0 | 0 | 0 | 10 | Q1 | 2 | 2 | ||||||||
| UM-M2-PHARMA-015-M Pharmacodépendance, toxicomanie et mésusage des médicaments | 4 | 6 | 0 | 0 | 0 | 10 | Q1 | 2 | 2 | ||||||||
| UM-M2-PHARMA-016-M Médicaments anticancéreux | 10 | 0 | 0 | 0 | 0 | 10 | Q1 | 2 | 2 | ||||||||
| UM-M2-PHARMA-017-M Introduction au métier de pharmacien hospitalier | 10 | 0 | 0 | 0 | 0 | 10 | Q1 | 2 | 2 | ||||||||
| UM-M2-PHARMA-018-M Les acides nucléiques, nouvelle source de thérapie personnalisée | 10 | 0 | 0 | 0 | 0 | 10 | Q1 | 2 | 2 | ||||||||
| UM-M2-PHARMA-019-M gestion des conduites | 5 | 15 | 0 | 0 | 0 | 20 | Q1 | 2 | 2 | ||||||||
| UM-M2-PHARMA-021-M Comptabilité et gestion officinale | 10 | 0 | 0 | 0 | 0 | 10 | Q1 | 2 | 2 | ||||||||
| UM-M2-PHARMA-022-M Pharmacovigilance | 10 | 0 | 0 | 0 | 0 | 10 | Q1 | 2 | 2 | ||||||||
| UM-M2-PHARMA-023-M Formes pharmaceutiques innovantes | 10 | 0 | 0 | 0 | 0 | 10 | Q1 | 2 | 2 | ||||||||
| UM-M2-PHARMA-033-M Analyses critiques d'études cliniques | 10 | 0 | 0 | 0 | 0 | 10 | Q1 | 2 | 2 | ||||||||
| Développement préclinique et industrie | 0 | ||||||||||||||||
| UM-M2-PHARMA-006-M Mémoire \ Industrie, recherche (1,5 mois) | 0 | 0 | 180 | 0 | 0 | 180 | Y | 15 | 15 | ||||||||
| Cours à option - Développement préclinique et industrie | 10 | ||||||||||||||||
| UM-M2-PHARMA-024-M Management et marketing pharmaceutique | 10 | 0 | 0 | 0 | 0 | 10 | Q1 | 2 | 2 | ||||||||
| UM-M2-PHARMA-025-M Développement pharmaceutique et industriel + visites industries | 12 | 0 | 0 | 0 | 0 | 12 | Q1 | 2 | 2 | ||||||||
| UM-M2-PHARMA-026-M Analyses critiques d'études cliniques | 10 | 0 | 0 | 0 | 0 | 10 | Q1 | 2 | 2 | ||||||||
| UM-M2-PHARMA-027-M Drug design | 10 | 0 | 0 | 0 | 0 | 10 | Q1 | 2 | 2 | ||||||||
| UM-M2-PHARMA-028-M Fractionnement bioguidé de produits naturels | 0 | 0 | 10 | 0 | 0 | 10 | Q1 | 2 | 2 | ||||||||
| UM-M2-PHARMA-029-M Formes pharmaceutiques innovantes | 10 | 0 | 0 | 0 | 0 | 10 | Q1 | 2 | 2 | ||||||||
| UM-M2-PHARMA-030-M Les acides nucléiques, nouvelle source de thérapie personnalisée | 10 | 0 | 0 | 0 | 0 | 10 | Q1 | 2 | 2 | ||||||||
| UM-M2-PHARMA-031-M Lab on a chip | 10 | 0 | 0 | 0 | 0 | 10 | Q1 | 2 | 2 | ||||||||
| UM-M2-PHARMA-032-M Intellectual Property | 14 | 0 | 0 | 0 | 0 | 14 | Q1 | 2 | 2 | ||||||||
| UM-M2-PHARMA-034-M Pharmacovigilance | 10 | 0 | 0 | 0 | 0 | 10 | Q1 | 2 | 2 | ||||||||
| UM-M2-PHARMA-035-M Initiation à la culture cellulaire et études de cytotoxicité | 10 | 5 | 0 | 0 | 0 | 15 | Q1 | 2 | 2 | ||||||||
| UM-M2-PHARMA-036-M Notions de Pharmacie humanitaire | 10 | 0 | 0 | 0 | 0 | 10 | Q1 | 2 | 2 | ||||||||
| Recherche | 0 | ||||||||||||||||
| UM-M2-PHARMA-008-M Mémoire \ Recherche (université, industrie, ... - 3 mois) | 0 | 0 | 480 | 0 | 0 | 480 | Y | 25 | 25 | ||||||||
| Séjour à l'étranger | 0 | ||||||||||||||||
| UM-M2-PHARMA-007-M Mémoire Etranger (3 mois) | 0 | 0 | 480 | 0 | 0 | 480 | Y | 25 | 25 | ||||||||
| 60 | |||||||||||||||||
(*) HT : Hours of theory - HTPE : Hours of in-class exercices - HTPS : hours of practical work - HD : HMiscellaneous time - HR : Hours of remedial classes. - Per. (Period), Y=Year, Q1=1st term et Q2=2nd term
Please note, the course titles given here are translations of the original titles and are provided in English for information only. In order to know in which language the course will be taught, please refer to the French page. There, the titles provided in French indicate that the course is taught in French and the titles provided in English indicate that the course is taught in English.